Abstract
PURPOSE: The aim of the present study was to investigate the effect of spirulina on lipid profiles and glycemic related markers in type 2 diabetes patients. METHODS: PubMed, Scopus, Cochrane Library, ISI Web of Science, and Google Scholar were searched from inception to August 2020. All clinical trials which investigated the effect of spirulina supplementation on glycemic related markers and lipid profile among type 2 diabetes patients were included. Random effects modeling was utilized for pooling analysis to compensate for the between-study heterogeneity. RESULTS: Eight studies (9 arms) were included in the meta-analysis. We found a significant reduction in fasting blood glucose (-17.88 mg/dl; 95% CI: -26.99, -8.78; I (2) : 25%), triglyceride (-30.99 mg/dl; 95% CI: -45.20, -16.77; I (2) : 50%), total-cholesterol (-18.47 mg/dl; 95% CI: -33.54, -3.39; I (2) : 73%), LDL-C (-20.04 mg/dl; 95% CI: -34.06, -6.02; I (2) : 75%), VLDL (-6.96 mg/dl; 95% CI: -9.71, -4.22; I (2) : 33%), in addition to a significant increase in HDL-C (-6.96 mg/dl; 95% CI: -9.71, -4.22; I (2) : 33%), after spirulina administration. No significant effect was observed on HbA1C or post prandial blood sugar following spirulina consumption. CONCLUSION: The present study suggests that spirulina supplementation can elicit beneficial effects on fasting blood glucose and blood lipid profiles. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40200-021-00760-z.